



Questionnaire

Please submit to nishita.shastri@breaksight.net

Name: _____

Institution/Company: _____

Email address: _____


Does your company or lab have an area of focus in DNA damage and/or genomic instability?

- Yes, we study mechanisms related to DNA damage and/or genomic instability
- Not really, but we are heading in that direction
- No, our work is not related to DNA damage or genomic instability


If you are a drug-developing company, how many drug candidates do you currently have in different phases of your drug developmental pipeline (including discovery, pre-clinical, clinical, and post-approval stages), and how many do you anticipate will enter your pipeline in the next quarter?

1. Discovery – _____
2. Pre-clinical – _____
3. Clinical
 - a. Phase 1 – _____
 - b. Phase 2 – _____
 - c. Phase 3 – _____
4. Post-approval – _____
5. Entering discovery phase in the incoming quarter – _____


Does your company or lab frequently perform genotoxicity assays (such as the Ames test, the Mouse Micronucleus test, or the Chromosomal Aberration test)? If so, would a deeper probe into the genome-wide locations of DNA double-stranded breaks resulting from treatment of cells with your drug candidates or compounds provide additional helpful information?

A large, empty rectangular box with a thin black border, intended for the user to provide a response to the question above.


BreakSight's services identify where DNA double-stranded breaks occur in the genome of cells exposed to treatment(s) that induces acute DNA damage during proliferation. Would this technology add value to your company or research to advance drug characterization and gain unique mechanistic insights, or is it similar to existing assays or screens that your company or lab employs? If so, which assay(s) or screen(s)?

A large, empty rectangular box with a thin black border, intended for the user to provide a response to the question above.


What does your bioinformatics team search for in NGS data? What applications do your company or lab utilize this data for?



What more would you like to see done to characterize your drug(s) or compounds? (i.e. more *in vitro* or *in vivo* studies, greater basic or mechanistic research, expanded biomarker identification, etc.)



Other comments or questions:

A large, empty rectangular box with a thin black border, intended for the respondent to provide additional comments or questions.

Thank you for taking the questionnaire!